持续性房颤的影响因素考察

摘要
图/表
参考文献(21)
相关文章 (15)

全文: PDF (0 KB) HTML (35 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨持续性房颤的相关危险因素并分析相关的临床意义。方法选择2015年1月～2017年3月在我科住院的房颤患者169例，根据欧洲心血管病学会心律失常工作组（WGA-ESC）和北美起搏与电生理学会（NASPE）的临床分类方法分为阵发性房颤组（53例）和持续性房颤组（116例），收集患者的一般资料、实验室检查和超声心动图检查结果等，用Logistic回归分析持续性房颤发生的危险因素。结果两组患者的性别、年龄、吸烟和饮酒率以及高血压、糖尿病、冠心病患病率等比较，差异无统计学意义（P＞0.05）。持续性房颤组患者的血尿酸（SUA）水平为（377.9±96.9）μmol/L，血 B 型脑钠肽前体（pro-BNP）水平为[1084.0（750.4，2238.3）]pg/ml，左心房内径（LAD）为（41.9±5.0）mm，均明显高于阵发性房颤组的（324.1±86.1）μmol/L、[175.3（99.0，529.7）]pg/ml、（35.8±5.0）mm，差异均有统计学意义（P<0.001）。逐步回归分析结果提示，SUA（OR=1.005，95%CI=1.001～1.010）、pro-BNP（OR=1.329，95%CI=1.000～1.001）以及 LAD（OR=1.329，95%CI=1.199～1.475）是发生持续性房颤的危险因素（P<0.05）。结论 SUA、pro-BNP水平以及LAD，可能是持续性房颤发生的危险因素。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	周恍
	殷跃辉

关键词 ：心房颤动, 尿酸, B型脑钠肽, 左心房内径

Abstract：Objective To explore the risk factors related to permanent atrial fibrillation(AF)and discuss the clinical significance.MethodsA total of 169 inpatients of our department with atrial fibrillation (AF)from January 2015 to March 2017 were consecutively enrolled in this study.They were divided into paroxysmal AF group (n=53)and permanent AF group(n=116)by the consensus of WGA-ESC and NASPE.The clinical data and the results of laboratory tests and ultrasound cardiograms were collected,risk factors of AF were analyzed by logistic regression analysis.Results There were no significant differences in gender,age,smoking,drinking,hypertension,diabetes or coronary heart disease between the two groups(P＞0.05).However,the levels of SUA (324.1±86.1 vs.377.9±96.9,P<0.001),pro-BNP(175.3[99.0,529.7]vs.1084.0[750.4,2238.3],P<0.001)and LAD(35.8±5.0 vs.41.9±5.0,P<0.001)were higher in permanent AF group rather than in paroxysmal group.The stepwise regression analysis results were showed,SUA (OR=1.005 [1.001-1.010],P=0.027),pro-BNP(OR=1.329[1.000-1.001],P=0.026)and LAD(OR=1.329[1.199-1.475],P=0.001)levels were the risk factors of the development of permanent AF.Conclusion The SVA,pro-BNP and LAD may bethe risk factors of the development of permanent AF.

Key words： Atrial fibrillation Uric acid BNP Left atrial diameter

通讯作者: 殷跃辉（1963-），男，上海人，硕士，教授，主任医师，研究方向：心血管疾病

作者简介: 周恍（1987-），女，重庆人，博士，住院医师，研究方向：心血管疾病

引用本文:

周恍;殷跃辉. 持续性房颤的影响因素考察[J]. 中国当代医药, 2018, 25(12): 51-53转57.
ZHOU Huang;YIN Yue-hui. Study of the risk factors related to permanent atrial fibrillation. 中国当代医药, 2018, 25(12): 51-53转57.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2018/V25/I12/51

[1]	余凌，金雪娥.坎地沙坦联合胺碘酮治疗老年高血压合并持续性房颤疗效评价[J].现代医院，2016，16（11）:1581-1583.
[2]	Liu Y.Hyperuricemia and Risk of Atrial Fibrillation[J].J Atr Fibrillation，2014，6（5）：967.
[3]	Lip GY，Laroche C，Ioachim PM，et al.Prognosis and treatment of atrial fibrillation patients by European cardiologists：one year follow-up of the EUR observational research programme-atrial fibrillation general registry pilot phase（EORP-AF Pilot registry）[J].Eur Heart J，2014，35 （47）：3365-3376.
[4]	Hu YF，Chen YJ，Lin YJ，et al.In ammation and the pathogenesis of atrial fibrillation[J].Nat Rev Cardiol，2015，12（4）：230-243.
[5]	Korantzopoulos P，Kolettis TM，Galaris D，et al.The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation[J].Int J Cardiol，2007，115（2）：135-143.
[6]	Terkeltaub R，Bushinsky DA，Becker MA.Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics[J].Arthritis Res Ther，2006，8Suppl 1：S4.
[7]	Kuo CF，Grainge MJ，Mallen C，et al.Impact of gout on the risk of atrial fibrillation[J].Heumatology，2016，55（4）：721-728.
[8]	Nyrnes A，Toft I，Njolstad I，et al.Uric acid is associated with future atrial fibrillation：an 11-year follow-up of 6308 men and women--the tromso study[J].Europace，2014，16（3）：320-326.
[9]	Chiang C，Naditch-Brulé L，Goethals M，et al.Distribution and risk profile of paroxysmal，persistent，and permanent atrial fibrillation in routine clinical practice：Insight from the real-life global survey evaluating patients with atrial fibrillation international registry[J].Circ Arrhythm Electrophysiol，2012，5（4）：632-639.
[10]	Letsas KP，Korantzopoulos P，Filippatos GS，et al.Uric acid elevation in atrial fibrillation[J].Hellenic J Cardiol，2010，51（3）：209-213.
[11]	Tamariz L，Agarwal S，Soliman EZ，et al.Association of serum uric acid with incident atrial fibrillation（from the atherosclerosis risk in communities[ARIC]study）[J].Am J Cardiol，2011，108（9）：1272-1276.
[12]	Tamariz L，Hernandez F，Bush A，et al.Association between serum uric acid and atrial fibrillation：a systematic review and meta-analysis[J].Heart Rhythm，2014，11（7）：1102-1108.
[13]	Chao TF，Hung CL，Chen SJ，et al.The association between hyperuricemia，left atrial size and new-onset atrial fibrillation[J].Int J Cardiol，2013，168（4）：4027-4032.
[14]	Kuo CF，Grainge MJ，Mallen C，et al.Impact of gout on the risk of atrial fibrillation[J].Rheumatology，2016，55（4）：721-728.
[15]	Perri L，Pastori D，Pignatelli P，et al.Flow-mediated dilation is associated with cardiovascular events in non-valvular atrial fibrillation patients[J].Int J Cardiol，2015，179：139-143.
[16]	OkawaK，MiyoshiT，TsukudaS，etal.Differencesinendothelial dysfunction induced by paroxysmal and persistent atrial fibrillation：Insights from restoration of sinus rhythm by catheter ablation[J].Int J Cardiol，2017，244：180-185.
[17]	Guo YG，Lip Y，Apostolakis S.Inflammation in atrial fibrillation[J].J Am CollCardiol，2012，60（22）：2263-2270.
[18]	Burstein B，Comtois P，Michael G，et al.Changes in connexin expression and the atrial fibrillation substrate in congestive heart failure[J].Circ Res，2009，105（12）：1213-1222.
[19]	Misawa T，Takahama M，Kozaki T，et al.Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome[J].Nat Immunol，2013，14（5）：454-460.
[20]	MacGowanSW，ReganMC，Malone C，et al.Superoxide radical and xanthine oxidoreductase activity in the human heart during cardiac operations[J].Ann Thorac Surg 1995，60（5）：1289-1293.
[21]	Ben Abraham R，Matza M，Marmor S，et al.Electromechanical impairment of human auricle and rat myocardial strip subjected to exogenous oxidative stress[J].Eur J Cardiothorac Surg，2003，23（1）： 66-73.